About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recu ...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--Colorectal Cancer Detection Is Primary Goal of Global Healthy Living Foundation and Guardant Health. ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Group 1 - Gamehost Inc. has declared a cash dividend of $0.05 (CDN) per common share for December 2025, which annualizes to $0.60 (CDN) per share [1] - The dividend will be paid on January 15, 2026, to shareholders of record on December 31, 2025 [1] - This dividend is classified as an "Eligible Dividend," qualifying for the enhanced gross-up and dividend tax credit for Canadian shareholders [2] Group 2 - Gamehost operates various facilities in Alberta, including the Rivers Casino & Entertainment Centre, Great Northern Casino, Service Plus Inns & Suites, Encore Suites hotels, and Deerfoot Inn & Casino [3] - The company's common shares are traded on the Toronto Stock Exchange (TSX) under the symbol GH [4] - Additional information and complete disclosure about the company can be found on its website and SEDAR+ [4]

Group 1 - BofA raised the price target on Guardant Health (GH) to $120 from $100 while maintaining a Buy rating on the shares [1] - The firm is updating price targets for Life Sciences & Diagnostic Tools stocks under its coverage [1] - Headwinds are expected to fade, with markets anticipated to normalize by 2026 [1] Group 2 - The firm believes the biggest upside for the sector will come from a return to spending by Biopharma [1] - BofA favors companies with higher exposure to research and development in the current market environment [1]

Core Insights - Guardant Health, Inc. has successfully launched FPG 360, an in-house liquid biopsy testing service at Policlinico Gemelli in Rome, Italy [1] - This launch is part of a series of public-private partnerships that Guardant Health has established with leading European academic and research hospitals [1] Company Developments - The introduction of FPG 360 marks a significant advancement in precision oncology services offered by Guardant Health [1] - The partnership with Policlinico Gemelli highlights the company's commitment to integrating its innovative testing solutions within prominent healthcare institutions in Europe [1]

Core Insights - The healthcare sector has outperformed all other sectors, including technology, since the beginning of September, with the State Street Health Care Select Sector SPDR ETF (XLV) rising by 13% during this period [2][5] - The Tema Oncology ETF (CANC) has experienced a significant increase of 28% since September and is up 41% year-to-date [2][5] Company Highlights - Revolution Medicines (RVMD) is the top holding in the Tema Oncology ETF, with a remarkable gain of 127% since August 11, attributed to its strong management and potential breakthrough in pancreatic cancer therapy [3][4] - Roche Holdings (RHHBY) is noted for its portfolio of cancer immunology drugs, trading at an attractive PE ratio of 15, and has a significant pipeline that could enhance its valuation, especially following a positive readout in a breast cancer trial [4][6] - Guardant Health (GH) specializes in diagnostics, particularly a liquid biopsy test for early cancer detection, which is particularly relevant for colorectal cancer, the fastest-growing cancer among young people in the US [6][7]

Group 1 - Guardant Health (GH) has significantly outperformed the Medical sector in 2023, with a year-to-date return of approximately 246.8% compared to the sector's average return of 7% [4] - The Zacks Rank for Guardant Health is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for GH's full-year earnings has increased by 3.7% over the past quarter, reflecting improving analyst sentiment [3] Group 2 - Guardant Health is part of the Medical - Biomedical and Genetics industry, which consists of 467 stocks and is currently ranked 77 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Biomedical and Genetics industry this year is 20%, indicating that Guardant Health is performing better than its peers [5] - Another notable stock in the Medical sector, Collegium Pharmaceutical (COLL), has a year-to-date return of 67% and is ranked 1 (Strong Buy) in the Zacks Rank [4][5]

Sector Performance - Healthcare has outperformed all other sectors since the start of September, rising 13% [2] - The State Street Health Care Select Sector SPDR ETF (XLV) leads this performance, followed by technology at 9% and utilities at 5% [2] Fund Performance - The Tema Oncology ETF (CANC) has seen a significant increase of 28% since September and is up 41% year-to-date [2] Key Holdings in Oncology - Revolution Medicines (RVMD) is the top holding in the Tema Oncology ETF, with a remarkable gain of 127% since August 11 [3] - Roche Holdings (RHHBY) is highlighted for its attractive PE ratio of 15 and a strong pipeline of cancer immunology drugs, including a recent positive trial readout in breast cancer [4][5] - Guardant Health (GH) is noted for its liquid biopsy test that can detect cancer early, particularly colorectal cancer, which is rapidly increasing among young people in the US [5][6]

Group 1 - Senator Sheldon Whitehouse (D-R.I.) disclosed three recent stock purchases on November 21, 2025, including two food and beverage stocks ahead of the holidays [2][5] - The senator's new holdings include Guardant Health and Hershey, while he previously purchased Coca-Cola shares in October 2024 and December 2023 [2][3] - The senator has sold shares of Magnificent Seven stocks, including Apple and NVIDIA, in multiple transactions throughout 2025 [3][5] Group 2 - The recent trades by Senator Whitehouse are relatively small compared to his previous transactions and have not garnered significant attention [5] - With the retirement of Rep. Nancy Pelosi in 2026, retail investors may need to monitor the trading activities of other Congress members for potential market outperformance [6]